Findings

What do systematic reviews say?

5 questions · 5 findings · 2 reviews

No studies found 3 · 60%GRADE not reported 0 · 0%Very low 0 · 0%Low 1 · 20%Moderate 1 · 20%High 0 · 0%

Mortality by day 30 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mortality by day 60 · non‐hospitalised individuals with COVID‐19 (asymptomatic and mild disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mortality by day 30 · hospitalised individuals with COVID‐19 (moderate to severe disease)

Casirivimab/imdevimab showed no clear difference in mortality by day 30 compared with usual care alone (moderate certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
RR 0.94 [0.87, 1.02]
1 study · 9785 participants
Moderate

Mortality by day 60 · hospitalised individuals with COVID‐19 (moderate to severe disease)

The review found no eligible studies for this question.

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies for treatment of COVID‐19 2021 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

All‐cause mortality by day 30 · SARS‐CoV‐2 uninfected people without defined exposure, or with potential exposure to SARS‐CoV‐2

Casirivimab/imdevimab showed no clear difference in all‐cause mortality by day 30 compared with placebo (low certainty).

1 finding from 1 review

SARS‐CoV‐2‐neutralising monoclonal antibodies to prevent COVID‐19 2022 · Cochrane Headline outcomes only
RR 3 [0.12, 73.43]
1 study · 1505 participants
Low